Johnson & Johnson Inventory Turnover Ratio 2010-2024 | JNJ

Current and historical inventory turnover ratio for Johnson & Johnson (JNJ) from 2010 to 2024. Inventory turnover ratio can be defined as a ratio showing how many times a company's inventory is sold and replaced over a period. Johnson & Johnson inventory turnover ratio for the three months ending March 31, 2024 was 0.30.
Johnson & Johnson Inventory Turnover Ratio Historical Data
Date
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $351.202B $85.159B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $708.775B 118.03
Novo Nordisk (NVO) Denmark $550.845B 45.38
Merck (MRK) United States $317.211B 83.49
AbbVie (ABBV) United States $291.555B 14.82
AstraZeneca (AZN) United Kingdom $211.944B 18.78
Novartis AG (NVS) Switzerland $196.211B 13.59
Pfizer (PFE) United States $143.772B 13.87
Sanofi (SNY) $114.819B 10.34
Innoviva (INVA) United States $0.929B 6.56